Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

IGR_JUNCONCO_STUDY_LM


ABSTRACT: Antineoplastic effects of siRNA against TMPRSS2-ERG junction oncogene in prostate cancer: from molecular and cellular studies to preclinical investigations. Background of the study.:TMPRSS2-ERG junction oncogene is present in more than 50% of patients with prostate cancer, and its expression is frequently associated with poor prognosis. We knockdown by siRNA the two TMPRSS2-ERG fusion variants (III and IV) most frequently identified in patients’ biopsies and found an inhibition of TMPRSS2-ERG of above 70% in human prostate cancer VCaP cell line expressing TMPRSS2-ERG junction oncogene. To point out genes regulated after TMPRSS2-ERG oncogene silencing, microarray analysis was performed.. Materiel and Methods. Human prostate cancer VCaP cell line expressing TMPRSS2-ERG oncogene (ATCC® CRL-28

ORGANISM(S): Homo sapiens

SUBMITTER: Philippe Dessen 

PROVIDER: E-MTAB-2838 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress